Frequently Asked Questions

KeyPura™ is DMC Biotechnologies’ family of high-purity inositol ingredients for nutrition, health and wellness formulations. The portfolio includes KeyPura™ myo-inositol and KeyPura™ D-chiro-inositol, giving formulators access to both inositol isomers from a single supplier.

Myo-inositol (MI) is a naturally occurring isomer of inositol found in foods including fruits, beans, grains and nuts. It plays roles in cellular signaling and metabolic function and has been widely studied across metabolic, reproductive, hormonal and other areas of human health.

KeyPura™ myo-inositol is DMC’s high-purity, traceable myo-inositol ingredient for use in health and wellness formulations.

D-chiro-inositol (DCI) is another naturally occurring isomer of inositol. Like myo-inositol, it has been studied for its role in cellular signaling and metabolic function, and the two inositols play complementary roles in the body.

KeyPura™ D-chiro-inositol provides formulators with a high-purity, traceable source of DCI produced by DMC.

Myo-inositol (MI) and D-chiro-inositol (DCI) are two naturally occurring forms, or isomers, of inositol. Although structurally related, they play different and complementary roles in cellular signaling, hormone regulation and metabolic function.

The two inositols have been studied individually and in combination, including in formulations for women’s reproductive and metabolic health.

Yes. DMC offers both KeyPura™ myo-inositol and KeyPura™ D-chiro-inositol, allowing formulators to source both inositol isomers from a single supplier and quality system.

KeyPura™ inositols are produced using precision fermentation with purified, food-grade dextrose, giving DMC greater control over feedstock, production and purification.

Unlike conventional production routes that may rely on corn-processing by-products or plant extraction, the KeyPura™ process is designed around high purity, traceability, consistent quality and responsible production. DMC also produces both KeyPura™ myo-inositol and D-chiro-inositol under the same quality system, simplifying sourcing for formulators using both isomers.

KeyPura™ inositols are designed for use across a range of nutrition, health, wellness and personal care formulations. Potential applications include dietary supplements, functional foods and beverages, prenatal and maternal nutrition, metabolic wellness products, men’s and women’s health formulations, infant nutrition and personal care products.

Yes. KeyPura™ myo-inositol is suited for dietary supplement formulations across a range of health and wellness categories, including women’s health, men’s health, metabolic wellness, reproductive health and other nutrition applications.

DMC can provide specifications and additional product information to support formulators evaluating KeyPura™ myo-inositol for a specific application.

Myo-inositol can be incorporated into food and beverage formats where the formulation and intended use are appropriate. KeyPura™ myo-inositol gives product developers a high-purity, traceable ingredient option for functional nutrition applications, including powders, mixes and beverage concepts.

Myo-inositol has been studied across reproductive and maternal health applications, and KeyPura™ myo-inositol can be evaluated for prenatal, preconception and maternal nutrition formulations. Its high purity and controlled production make it particularly relevant to formulations where ingredient quality and consistency are important.

Myo-inositol occurs naturally in human breast milk and is used in infant formula to help mirror naturally occurring levels. It has also been studied in relation to early development. KeyPura™ myo-inositol provides a high-purity ingredient option for formulators evaluating myo-inositol for infant and specialized nutrition applications.

Inositol can also be used in personal care applications, including skin and hair formulations. KeyPura™ gives beauty and personal care formulators access to high-purity, traceable inositol with a clean ingredient provenance story.

The right ingredient depends on the application, formulation goals and intended product positioning. KeyPura™ myo-inositol and D-chiro-inositol can be used individually or considered together depending on the formulation.

DMC’s team can help you evaluate the appropriate KeyPura™ ingredient and provide specifications, samples and supporting documentation for your application.

Yes. Myo-inositol has been evaluated in clinical research across metabolic, reproductive, hormonal and other areas of health. Research includes randomized controlled trials and systematic reviews, including studies involving women with PCOS.

The evidence varies by application and outcome, so DMC presents this research as scientific background rather than as health claims for KeyPura™ myo-inositol.

Yes. D-chiro-inositol has been studied both independently and in combination with myo-inositol, particularly in research involving insulin signaling, metabolic health and PCOS.

Research continues to examine the distinct and complementary physiological roles of myo-inositol and D-chiro-inositol and how factors such as dose and ratio may influence outcomes.

Yes. Myo-inositol and D-chiro-inositol have been extensively studied in women with Polycystic Ovary Syndrome (PCOS), with research examining metabolic, hormonal and reproductive outcomes.

Systematic reviews and meta-analyses have evaluated inositol supplementation in PCOS, although findings vary by outcome, formulation and study design and the overall evidence remains uncertain for some outcomes.

DMC’s KeyPura™ materials use the term Polyendocrine Metabolic Ovarian Syndrome (PMOS), previously known as PCOS, when discussing this area of women’s health.

Clinical research has examined myo-inositol in relation to metabolic, hormonal and reproductive outcomes in women with PCOS, including insulin-related measures and ovarian function.

Results across studies are not uniform. Some reviews report potential benefits for selected outcomes, while others emphasize limitations in study quality, heterogeneity and the need for additional high-quality research.

Myo-inositol and D-chiro-inositol participate in insulin-signaling pathways and have been studied in relation to insulin sensitivity, glucose metabolism and other metabolic measures.

Clinical research has examined these relationships in several populations, including women with PCOS, but findings vary depending on the population, inositol form, dose and outcome studied.

Yes. Myo-inositol has been studied across female and male reproductive health, including research examining ovarian function, oocyte quality and assisted reproduction, as well as male reproductive parameters.

The results depend on the population and outcome studied, and research in this area continues to evolve.

Yes. Inositols have been studied in men across reproductive and metabolic health applications. Myo-inositol research has examined sperm-related parameters, while D-chiro-inositol research has explored metabolic and hormonal pathways relevant to men’s health.

DMC separates these areas of scientific research from product-specific health claims and can provide supporting literature for formulators evaluating inositols for men’s health applications.

The 40:1 inositol ratio refers to a formulation containing 40 parts myo-inositol (MI) for every 1 part D-chiro-inositol (DCI). This MI-to-DCI ratio has been studied extensively in women’s health research, including studies involving women with PCOS/PMOS.

Myo-inositol and D-chiro-inositol are related but distinct inositol isomers that play complementary roles in cellular signaling and metabolic function.

Myo-inositol and D-chiro-inositol are naturally occurring inositol isomers with distinct and complementary physiological roles. Research has examined the two individually as well as in combination, particularly in metabolic and reproductive health.

Combining MI and DCI allows formulators to include both inositol forms in a single formulation while controlling the amount and ratio of each.

MI and DCI are not interchangeable, and their relative amounts can be important when the two are formulated together. Different tissues maintain different relationships between the two isomers, and research has examined how the MI-to-DCI ratio may influence metabolic and reproductive applications.

The 40:1 ratio is one of the combinations studied in the scientific literature, particularly in research involving PCOS/PMOS.

There is no single MI-to-DCI ratio that should be described as universally “best” for every population or application. The 40:1 ratio has been widely used and studied in women’s health and PCOS research, but the appropriate formulation depends on the intended application, dose and supporting scientific evidence.

Product developers should evaluate the available research and applicable regulatory requirements when determining an appropriate formulation.

Yes. Clinical research has examined combinations of myo-inositol and D-chiro-inositol, including the 40:1 ratio, in women with Polycystic Ovary Syndrome (PCOS). Studies have investigated a range of metabolic, hormonal and reproductive outcomes.

Results should be interpreted within the context of individual study design, population and endpoints, and research findings should not be interpreted as health claims for KeyPura™.

Yes. DMC offers KeyPura™ myo-inositol and KeyPura™ D-chiro-inositol, allowing formulators to source both inositol isomers from a single supplier and quality system.

Sourcing myo-inositol and D-chiro-inositol from the same supplier can simplify ingredient qualification, documentation and supply management for formulations using both isomers.

DMC produces KeyPura™ myo-inositol and D-chiro-inositol under the same quality system, giving formulators a consistent provenance and documentation story across both ingredients.

I definitely want this question because it resolves a very practical ambiguity created by all our 40:1 messaging.

Hannah’s draft indicates separate specifications are available, but I’d have the team confirm exactly how the products are commercially offered before publishing the answer.

KeyPura™ myo-inositol is produced through precision fermentation using purified, food-grade dextrose as the feedstock. DMC’s controlled production and purification process is designed to deliver high-purity, consistent and traceable myo-inositol for health and wellness formulations.

KeyPura™ D-chiro-inositol is produced through precision fermentation using purified, food-grade dextrose. This controlled production route allows DMC to produce D-chiro-inositol to a defined specification while supporting consistent quality and scalable supply.

Conventional myo-inositol production commonly begins with phytic acid derived from corn-processing by-products and uses hydrolysis to produce the final ingredient. D-chiro-inositol may be sourced through extraction from plant material.

KeyPura™ takes a different approach. DMC uses precision fermentation with purified, food-grade dextrose, providing greater control over the starting feedstock, production process and purification while supporting high purity, consistent quality and traceability.

DMC’s KeyPura™ production process introduces no solvents during production. The streamlined process is designed to eliminate several processing steps associated with conventional manufacturing while supporting ingredient purity and responsible production.

For DMC, traceability means knowing the defined source and production pathway behind the ingredient. KeyPura™ is produced from purified, food-grade dextrose through a controlled process with defined specifications, giving formulators a clear provenance story and consistent documentation for the ingredient they source.

KeyPura™ myo-inositol and D-chiro-inositol are produced to defined quality specifications, including a minimum assay of 97.0%. Additional specifications covering microbiological limits, organic impurity profiles and other quality parameters are available from DMC upon request.

To request a sample of KeyPura™ myo-inositol or D-chiro-inositol, complete DMC’s contact form and select Product or Sample Inquiry. Let us know which KeyPura™ ingredient you’re interested in and tell us a little about your application so our team can follow up with the appropriate information.

Product specifications and supporting technical documentation for KeyPura™ myo-inositol and D-chiro-inositol are available from DMC upon request. Use our contact form to identify the ingredient and information you need, and our team will connect you with the appropriate documentation.

DMC can provide product information, technical documentation and ingredient-specific support to help customers evaluate KeyPura™ for their applications. For questions related to a particular formulation or product concept, contact our team with details about what you’re developing.

For current pricing, availability and commercial inquiries, contact the DMC team with the KeyPura™ ingredient, intended application and approximate requirements. A member of our team will follow up to discuss your needs.

DMC’s team can help with samples, specifications, commercial inquiries, ingredient questions and application support. Submit an inquiry through our contact form and select the options that best describe what you’re looking for so we can connect you with the right person.